MRKR Marker Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: MRKR
Price (delayed)
$0.9197
Market cap
$11.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.37
Enterprise value
$84,970
Relative Growth:
Rel. Growth:
60
Relative Strength:
Rel. Strength:
4
Relative Valuation:
Rel. Valuation:
19
Relative Profitability:
Rel. Profitability:
23
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy
Highlights
MRKR's revenue is up by 45% year-on-year but it is down by 5% since the previous quarter
Marker Therapeutics's gross profit has increased by 45% YoY but it has decreased by 5% QoQ
Marker Therapeutics's quick ratio has plunged by 51% from the previous quarter and by 40% YoY
MRKR's net income is down by 41% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of MRKR
Market
Valuations
Earnings
Shares outstanding
12.94M
Market cap
$11.9M
Enterprise value
$84,970
Price to earnings (P/E)
N/A
Price to book (P/B)
0.99
Price to sales (P/S)
2.38
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.02
Revenue
$5.39M
Gross profit
$5.39M
Operating income
-$15.13M
Net income
-$14.61M
EBIT
-$14.56M
EBITDA
-$14.56M
Free cash flow
-$10.88M
Per share
Balance sheet
Liquidity
EPS
-$1.37
EPS diluted
-$1.37
Free cash flow per share
-$0.78
Book value per share
$0.93
Revenue per share
$0.39
TBVPS
$1.06
Total assets
$14.77M
Total liabilities
$4.28M
Debt
$0
Equity
$10.49M
Working capital
$10.49M
Debt to equity
0
Current ratio
3.45
Quick ratio
3.15
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
-270.2%
Gross margin
100%
Net margin
-271.1%
Operating margin
-280.8%
Return on assets
-90.3%
Return on equity
-114.6%
Return on invested capital
N/A
Return on capital employed
-138.8%
Return on sales
-270.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRKR stock price
How has the Marker Therapeutics stock price performed over time
Intraday
0.28%
1 week
-6.87%
1 month
-14.84%
1 year
-75.54%
YTD
-70.43%
QTD
3.04%
Financial performance
How have Marker Therapeutics's revenue and profit performed over time
Revenue
$5.39M
Gross profit
$5.39M
Operating income
-$15.13M
Net income
-$14.61M
Gross margin
100%
Net margin
-271.1%
MRKR's revenue is up by 45% year-on-year but it is down by 5% since the previous quarter
Marker Therapeutics's gross profit has increased by 45% YoY but it has decreased by 5% QoQ
MRKR's net income is down by 41% year-on-year and by 14% since the previous quarter
Marker Therapeutics's operating income has decreased by 38% YoY and by 15% from the previous quarter
Price vs fundamentals
How does MRKR's price correlate with its fundamentals
Growth
What is Marker Therapeutics's growth rate over time
Valuation
What is Marker Therapeutics stock price valuation
P/E
N/A
P/B
0.99
P/S
2.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.02
The EPS is down by 16% year-on-year and by 3% since the previous quarter
The P/B is 53% below the 5-year quarterly average of 2.1 and 48% below the last 4 quarters average of 1.9
Marker Therapeutics's equity has decreased by 28% from the previous quarter but it has increased by 8% YoY
MRKR's P/S is 93% below its 5-year quarterly average of 34.8 and 37% below its last 4 quarters average of 3.8
MRKR's revenue is up by 45% year-on-year but it is down by 5% since the previous quarter
Efficiency
How efficient is Marker Therapeutics business performance
The ROE is down by 44% year-on-year and by 12% since the previous quarter
The ROA has contracted by 36% YoY and by 9% from the previous quarter
The ROS is down by 21% since the previous quarter but it is up by 2.8% year-on-year
Dividends
What is MRKR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRKR.
Financial health
How did Marker Therapeutics financials performed over time
MRKR's total liabilities has surged by 117% year-on-year and by 71% since the previous quarter
Marker Therapeutics's quick ratio has plunged by 51% from the previous quarter and by 40% YoY
The company's debt is 100% lower than its equity
Marker Therapeutics's equity has decreased by 28% from the previous quarter but it has increased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.